SI1019395T1 - Farnesyl transferase inhibiting 2-quinolone derivatives - Google Patents

Farnesyl transferase inhibiting 2-quinolone derivatives

Info

Publication number
SI1019395T1
SI1019395T1 SI9630453T SI9630453T SI1019395T1 SI 1019395 T1 SI1019395 T1 SI 1019395T1 SI 9630453 T SI9630453 T SI 9630453T SI 9630453 T SI9630453 T SI 9630453T SI 1019395 T1 SI1019395 T1 SI 1019395T1
Authority
SI
Slovenia
Prior art keywords
farnesyl transferase
quinolone derivatives
transferase inhibiting
inhibiting
quinolone
Prior art date
Application number
SI9630453T
Other languages
English (en)
Slovenian (sl)
Inventor
David William End
Marc Gaston c/o Janssen Cilag VENET
Patrick Rene c/o Janssen Cilag ANGIBAUD
Gerard Charles c/o Janssen Cilag SANZ
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of SI1019395T1 publication Critical patent/SI1019395T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI9630453T 1995-10-31 1996-10-25 Farnesyl transferase inhibiting 2-quinolone derivatives SI1019395T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP95202945 1995-10-31
EP96937249A EP1019395B1 (en) 1995-10-31 1996-10-25 Farnesyl transferase inhibiting 2-quinolone derivatives
PCT/EP1996/004661 WO1997016443A1 (en) 1995-10-31 1996-10-25 Farnesyl transferase inhibiting 2-quinolone derivatives

Publications (1)

Publication Number Publication Date
SI1019395T1 true SI1019395T1 (en) 2002-06-30

Family

ID=8220785

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9630453T SI1019395T1 (en) 1995-10-31 1996-10-25 Farnesyl transferase inhibiting 2-quinolone derivatives

Country Status (28)

Country Link
US (1) US5968952A (cs)
EP (2) EP1019395B1 (cs)
JP (1) JP4257869B2 (cs)
KR (1) KR100417620B1 (cs)
CN (1) CN1101391C (cs)
AR (1) AR004699A1 (cs)
AT (2) ATE269322T1 (cs)
AU (1) AU712435B2 (cs)
CA (1) CA2231143C (cs)
CY (1) CY2287B1 (cs)
CZ (1) CZ290954B6 (cs)
DE (2) DE69618999T2 (cs)
DK (1) DK1019395T3 (cs)
EA (1) EA000719B1 (cs)
ES (2) ES2233557T3 (cs)
HU (1) HU224032B1 (cs)
IL (1) IL123567A (cs)
MY (1) MY116577A (cs)
NO (1) NO314037B1 (cs)
NZ (1) NZ321576A (cs)
PL (1) PL184168B1 (cs)
PT (1) PT1019395E (cs)
SI (1) SI1019395T1 (cs)
SK (1) SK282642B6 (cs)
TR (1) TR199800720T2 (cs)
TW (1) TW349948B (cs)
WO (1) WO1997016443A1 (cs)
ZA (1) ZA969087B (cs)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE222104T1 (de) * 1997-06-02 2002-08-15 Janssen Pharmaceutica Nv (imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen
US6565831B1 (en) 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
CA2312720A1 (en) 1997-12-11 1999-06-17 Janssen-Cilag S.A. Retinoic acid mimetic anilides
US6420555B1 (en) * 1998-06-16 2002-07-16 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
ATE262520T1 (de) * 1998-06-16 2004-04-15 Sod Conseils Rech Applic Imidazol-derivate
US6545020B1 (en) * 1998-07-06 2003-04-08 Janssen Pharmaceutica, N.V. Farnesyl Protein transferase inhibitors with in vivo radiosensitizing properties
HRP20000904A2 (en) 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
FR2780892B1 (fr) * 1998-07-08 2001-08-17 Sod Conseils Rech Applic Utilisation d'inhibiteurs de prenyltransferases pour preparer un medicament destine a traiter les pathologies qui resultent de la fixation membranaire de la proteine g heterotrimerique
ES2237125T3 (es) * 1998-08-27 2005-07-16 Pfizer Products Inc. Derivados de quinolin-2-ona utiles como agentes anticancerigenos.
ATE321037T1 (de) 1998-08-27 2006-04-15 Pfizer Prod Inc Als antikrebsmittel verwendbare alkinyl- substituierte chinolin-2-on-derivate
AU2478500A (en) 1998-12-08 2000-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU2477400A (en) 1998-12-08 2000-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
TW531533B (en) * 1998-12-23 2003-05-11 Janssen Pharmaceutica Nv 1,2-annelated quinoline derivatives having farnesyl transferase and geranylgeranyl transferase inhibiting activity
ES2243228T3 (es) 1999-02-11 2005-12-01 Pfizer Products Inc. Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agentes anticancerigenos.
US6143766A (en) * 1999-04-16 2000-11-07 Warner-Lambert Company Benzopyranone and quinolone inhibitors of ras farnesyl transferase
EP1420015A1 (en) * 1999-06-11 2004-05-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Imidazolyl derivatives
PT1106612E (pt) 1999-11-30 2004-06-30 Pfizer Prod Inc Derivados de quinolina uteis para inibir a farnesil-proteina-transferase
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
DE60130976T2 (de) 2000-02-24 2008-07-17 Janssen Pharmaceutica N.V. Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
CA2397253A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
EP1263437A2 (en) * 2000-02-29 2002-12-11 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
CA2397240A1 (en) * 2000-02-29 2001-09-07 Peter Albert Palmer Farnesyl protein transferase inhibitor combinations with camptothecin compounds
WO2001064198A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
EP1261348A2 (en) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
WO2001064218A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations
WO2001064226A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with platinum compounds
AU2001256166A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
JP2003525239A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ タキサン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
WO2001064252A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
EP1267929A2 (en) * 2000-02-29 2003-01-02 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with an her2 antibody
US6844357B2 (en) * 2000-05-01 2005-01-18 Pfizer Inc. Substituted quinolin-2-one derivatives useful as antiproliferative agents
JO2361B1 (en) * 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
WO2002024682A1 (en) * 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
JP4974437B2 (ja) * 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−［（置換フェニル）メチル］−キノリンおよびキナゾリン誘導体
AU2001293835A1 (en) * 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
US7153958B2 (en) 2000-11-21 2006-12-26 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting benzoheterocyclic derivatives
EP1339407B1 (en) * 2000-11-28 2006-04-19 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease
EP1395577A1 (en) * 2000-12-19 2004-03-10 Pfizer Products Inc. Crystal forms of 6- (4-chloro-phenyl)-hydroxy-(-3-methyl-3h-imidaol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
WO2002051835A1 (en) * 2000-12-27 2002-07-04 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
US20040067968A1 (en) * 2000-12-27 2004-04-08 Angibaud Patrick Rene Farnesyl transferase inhibiting 4-heterocyclyl quinoline and quinazoline
DE60230017D1 (de) * 2001-02-15 2009-01-08 Janssen Pharmaceutica Nv Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
AU2002253101B2 (en) 2001-03-12 2007-08-09 Janssen Pharmaceutica N.V. Process for the preparation of imidazole compounds
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
DE60231646D1 (de) 2001-12-19 2009-04-30 Janssen Pharmaceutica Nv Durch c-verbundene imidazole substituierte 1,8-annellierten chinolon-derivate als farnesyl transferase inhibitoren
WO2003080058A1 (en) * 2002-03-22 2003-10-02 Janssen Pharmaceutica. N.V. Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
ES2271574T3 (es) 2002-04-15 2007-04-16 Janssen Pharmaceutica N.V. Derivados triciclicos de quinazolina inhibidores de la farnesiltransferasa, sustituidos con imidazoles o triazoles enlazados al carbono.
FR2841243B1 (fr) * 2002-06-19 2004-08-20 Servier Lab Nouveaux derives de 3-(4-oxo-4h-chromen-2yl)-(1h)-quinolein- 4-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20030125268A1 (en) * 2002-08-28 2003-07-03 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
FR2860235A1 (fr) * 2003-09-29 2005-04-01 Yang Ji Chemical Company Ltd Utilisation d'un compose de formule (i) inhibiteur de l'aromatase a des fins therapeutiques et composes de formule (i) en tant que tels
US20050272068A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. UCH-L1 expression and cancer therapy
EP2433634A3 (en) * 2004-09-17 2012-07-18 The Whitehead Institute for Biomedical Research Compounds, compositions and methods of inhibiting a-synuclein toxicity
SI2362218T1 (sl) 2004-11-05 2014-12-31 Janssen Pharmaceutica N.V. Postopki za spremljanje učinkovitosti inhibitorjev farneziltransferaze
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US20060281769A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US20070004660A1 (en) * 2005-06-10 2007-01-04 Baumann Christian A Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
US20060281755A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US7833339B2 (en) 2006-04-18 2010-11-16 Franklin Industrial Minerals Mineral filler composition
JP2009521470A (ja) 2005-12-23 2009-06-04 リンク メディシン コーポレイション シヌクレイン障害の治療
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
EP2021335B1 (en) 2006-04-20 2011-05-25 Janssen Pharmaceutica N.V. Heterocyclic compounds as inhibitors of c-fms kinase
ES2565238T3 (es) 2006-04-20 2016-04-01 Janssen Pharmaceutica N.V. Inhibidores de la c-fms quinasa
DE102007015709B4 (de) 2007-01-25 2009-09-03 Webasto Ag Fahrzeugdach
PE20090326A1 (es) 2007-06-05 2009-04-04 Schering Corp Compuestos heterociclos como inhibidores de erk
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
WO2009117484A2 (en) 2008-03-18 2009-09-24 University Of South Florida Small molecule e2f inhibitor
BRPI0920927A2 (pt) 2008-11-13 2019-09-24 Link Medicine Corp derivados de azaquinolinona e usos dos mesmos
WO2011041152A1 (en) 2009-09-30 2011-04-07 Schering Corporation Novel compounds that are erk inhibitors
CA2794112A1 (en) 2010-04-06 2011-10-13 Brigham Young University Antimetastatic compounds
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
CA3186328A1 (en) 2010-07-28 2012-02-02 Janssen Pharmaceutica Nv Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors
US20130158035A1 (en) * 2010-08-24 2013-06-20 Brigham Young University Antimetastatic compounds
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US9175001B2 (en) 2011-10-02 2015-11-03 Trustees Of Boston University [1,3] dioxolo [4,5-g] [1,2,4] triazolo [1,5-a] quinoline derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
US9303046B2 (en) 2012-08-07 2016-04-05 Janssen Pharmaceutica Nv Process for the preparation of heterocyclic ester derivatives
WO2015119249A1 (ja) 2014-02-07 2015-08-13 国立大学法人東京医科歯科大学 筋形成促進剤、筋萎縮抑制剤、医薬組成物及びｔａｚ活性化剤
TWI710642B (zh) 2015-08-17 2020-11-21 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶（farnesyltransferase）抑制劑治療癌症病患之方法
EP3133066A1 (en) 2015-08-21 2017-02-22 Merck Patent GmbH Hydrophilic compounds for optically active devices
EP3133065A1 (en) 2015-08-21 2017-02-22 Merck Patent GmbH Compounds for optically active devices
WO2017034877A1 (en) * 2015-08-27 2017-03-02 Janssen Pharmaceutica Nv Chemically modified quinoline and quinolone derivatives useful as cb-1 inverse agonists
KR20190082247A (ko) 2016-11-03 2019-07-09 쿠라 온콜로지, 인크. 파르네실전달효소 억제제를 이용하여 암 환자를 치료하는 방법
EP3363793A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Hydrophobic compounds for optically active devices
EP3363786A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Compounds for optically active devices
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
TW202108170A (zh) 2019-03-15 2021-03-01 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3900501A (en) * 1970-12-23 1975-08-19 Hoffmann La Roche Benzophenone intermediates for 7-lower alkanoyl benzodiazepines
IL65709A (en) * 1981-05-18 1986-01-31 Chevron Res Electroactive polymers
JPS63275548A (ja) * 1987-05-02 1988-11-14 Res Inst For Prod Dev ｏ−アミノベンゾイル化合物の製造方法
CA2002864C (en) * 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
CA2002859C (en) * 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders
EP0574992A1 (en) * 1992-06-17 1993-12-22 Glaxo Group Limited 5-(1,2,4-Triazol-1-ylmethyl)-3H-isobenzofuran-1-one derivatives, their preparation and use as aromatase inhibitors
ES2134971T3 (es) * 1994-04-15 1999-10-16 Takeda Chemical Industries Ltd Derivado de acido octahidro-2-naftaleno-carboxilico, su produccion y uso.

Also Published As

Publication number Publication date
ES2233557T3 (es) 2005-06-16
HUP9802424A2 (hu) 1999-10-28
US5968952A (en) 1999-10-19
HUP9802424A3 (en) 2003-02-28
HK1036064A1 (en) 2001-12-21
CA2231143A1 (en) 1997-05-09
CY2287B1 (en) 2003-07-04
DE69632751D1 (de) 2004-07-22
WO1997016443A1 (en) 1997-05-09
NO314037B1 (no) 2003-01-20
AU7493396A (en) 1997-05-22
PL184168B1 (pl) 2002-09-30
HU224032B1 (hu) 2005-05-30
TW349948B (en) 1999-01-11
DK1019395T3 (da) 2002-05-06
AU712435B2 (en) 1999-11-04
EA000719B1 (ru) 2000-02-28
ZA969087B (en) 1998-04-29
EP1106610B1 (en) 2004-06-16
EP1019395B1 (en) 2002-01-30
DE69632751T2 (de) 2005-08-04
CN1200732A (zh) 1998-12-02
SK282642B6 (sk) 2002-10-08
JPH11514635A (ja) 1999-12-14
ATE269322T1 (de) 2004-07-15
DE69618999T2 (de) 2002-09-26
SK55698A3 (en) 1999-02-11
PL328230A1 (en) 1999-01-18
KR19990063639A (ko) 1999-07-26
NO980928L (no) 1998-04-29
AR004699A1 (es) 1999-03-10
KR100417620B1 (ko) 2004-05-27
NO980928D0 (no) 1998-03-04
CN1101391C (zh) 2003-02-12
MY116577A (en) 2004-02-28
CA2231143C (en) 2005-06-21
EP1106610A1 (en) 2001-06-13
NZ321576A (en) 1999-05-28
HK1027576A1 (en) 2001-01-19
EP1019395A1 (en) 2000-07-19
JP4257869B2 (ja) 2009-04-22
TR199800720T2 (xx) 1998-09-21
CZ290954B6 (cs) 2002-11-13
MX9802067A (es) 1998-08-30
ATE212627T1 (de) 2002-02-15
IL123567A0 (en) 1998-10-30
CZ127298A3 (cs) 1998-12-16
DE69618999D1 (de) 2002-03-14
PT1019395E (pt) 2002-07-31
ES2171736T3 (es) 2002-09-16
IL123567A (en) 2002-11-10
EA199800395A1 (ru) 1998-10-29

Similar Documents

Publication Publication Date Title
HUP9802424A3 (en) Farnesyl transferase inhibiting 2-quinolone derivatives
IL123155A0 (en) 4-mercaptopyrrolidine derivatives as farnesyl transferase inhibitors
IL123568A0 (en) Farnesyl protein transferase inhibiting (imidazol-5-yl) methyl-2-quinolinone derivatives
EP0833633A4 (en) INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
IL122812A0 (en) 4,9-ethano-benzo (F) isoindole derivatives as farnesyl transferase inhibitors
HU9602516D0 (en) Isoprenyl transferase inhibitors
IL124522A0 (en) Quinoline derivatives
GB9505864D0 (en) Hydrate Inhibition
EP0817630A4 (en) INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
GB9506174D0 (en) Inhibitors of farnesyl-protein transferase
GB9524976D0 (en) Subsea clamp
IL130453A0 (en) Farnesyl transferase inhibitors
ZA958225B (en) Inhibitors of farnesyl-protein transferase
ZA971254B (en) Farnesyl transferase inhibitors
IL155594A0 (en) Farnesyl transferase inhibitors
SI0948483T1 (en) Farnesyl transferase inhibitors
IL141626A0 (en) Farnesyl transferase inhibitors
GB2307940B (en) Subsea clamp
ZA962433B (en) Inhibitors of farnesyl-protein transferase
GB9610174D0 (en) Prenyl transferase inhibitors
GB9519595D0 (en) Inetellectual sovereignty
ZA958162B (en) Inhibitors of farnesyl-protein transferase
GB9509472D0 (en) Diazinone derivatives